Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Resolves Trovan Litigation In Nigeria, But More Suits Remain

Executive Summary

Pfizer freed itself from the bulk of litigation over a 1996 Trovan clinical trial in Nigeria, agreeing to pay $75 million to settle civil and criminal charges brought by the Kano State government in Nigeria. The sum is a fraction of the more the $9 billion in claims the company was facing

You may also be interested in...



Out Of Africa: Why A Court Decision On Trovan Affects Pharma

Last month, a federal appeals panel jolted Pfizer by ruling that dozens of Nigerians can sue the drugmaker in a U.S. court over its handling of a 1996 clinical trial for its Trovan (trovafloxacin mesylate) antibiotic

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel